Initial results from the OpenMind study, the largest behavioural study to look at both patients' and physicians' perceptions of HIV care in treatment-experienced patients, were revealed today at EACS. The study's findings are anticipated to help physicians implement improved care to HIV patients and help pave the way for better acceptance and integration of other new innovative drugs such as monoclonal antibodies that are increasingly being developed for the management of HIV and other diseases.
The study was conceived to look at attitudes to FUZEON (enfuvirtide), the first approved HIV fusion inhibitor, and an important option for treatment-experienced patients who face HIV resistance. FUZEON presents unique challenges because it is the first self-injectable antiretroviral whereas all other treatments are oral.
Highlights from today's data show that:
- Patients are more willing to consider and use self-injectable therapy than many physicians anticipate
- Three-quarters (76%) of patients would consider using a self-injectable HIV therapy if their physician recommended it
- Worryingly, only one quarter (28%) of patients who are potentially eligible for FUZEON had actually discussed this injectable option with their physicians
- Only 10% of eligible patients were currently prescribed FUZEON, despite the fact that it is recommended in key international HIV treatment guidelines
This study also identifies some of the main reasons why many physicians may be reluctant to prescribe a treatment of proven efficacy and safety. The reasons include; the physicians' perception that patients would be reluctant to use a self-injectable therapy, the physicians' opinion that the patient would not be able to incorporate FUZEON into their lifestyle and the potential misconception that FUZEON is not appropriately recommended in guidelines.
"Physicians' best intentions in trying to match treatments tPage: 1 2 Related medicine news :1
Contact: Kate Pogson
. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals2
. Penn study finds pro-death proteins required to regulate healthy immune function3
. New study shows promise in reducing surgical risks associated with surgical bleeding4
. New study counts the economic cost of persistent pain in Australia5
. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA6
. Most seniors now have drug coverage, U-M study shows7
. To gain muscle and lose fat, drink milk: study8
. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests9
. Even older women at high risk have little interest in being tested for HIV, study finds10
. Metabolic study in mice could lead to good cholesterol boosters11
. Michigan-CDC study supports value of social restrictions during influenza pandemics